ArticleInternational journal of clinical pharmacy2026
Bibliometric analysis of anti-angiogenic therapy in gastric cancer: research hotspots, trends, and emerging frontiers.
Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionAnti-angiogenic therapy has demonstrated therapeutic potential for several malignancies; however, its clinical efficacy in gastric cancer (GC) remains limited. To better understand the evolution of this field, comprehensive bibliometric analysis is required to map research trends, identify key contributors, and highlight emerging hotspots.
aimThis study aimed to systematically map the research landscape of anti-angiogenic therapy for gastric cancer and identify key trends, hotspots, and emerging fronts using a bibliometric analysis.
methodPublications related to anti-angiogenic therapy in GC were retrieved from the Science Citation Index Expanded (SCIE) and the Social Science Citation Index (SSCI) within the Web of Science Core Collection (WoSCC), covering 2000 to 2024. Microsoft Excel 365 was used to plot annual publication trends. VOSviewer was used to construct collaboration networks between countries/regions, institutions, authors, and co-cited references. CiteSpace was used to conduct keyword co-occurrence and burst analysis.
resultsIn total, 916 publications were identified, comprising 698 articles and 218 reviews. The annual output increased steadily after 2003, peaking at 63 publications by 2021. China was the most productive country, followed by the USA, and both countries demonstrated a close collaborative relationship. The leading publishing institutions are primarily Chinese, including Shanghai Jiao Tong University, Nanjing Medical University, and Sun Yat-sen University. The most productive authors were Masakazu Yashiro, followed by Giuseppe Aprile, and Jin Li. The co-citation analysis identified landmark references by Fuchs (Lancet 383:31-39, 2014, 153 citations), Wilke (Lancet Oncol 15:1224-1235, 2014, 143 citations), and Ohtsu (J Clin Oncol 29:3968-3976, 2011, 133 citations) as central to the field. Keyword analysis revealed that early research has focused on "gastric cancer," "angiogenesis," and "bevacizumab." More recent hotspots shifted toward targeted therapy and clinical trial terminology, such as "first-line therapy," "randomized phase III," "supportive care," and "chemotherapy." Citation burst analysis highlighted emerging strategies, with frequent bursts for "nivolumab," "open label," and "plus chemotherapy," reflecting the integration of immunotherapy and multimodal regimens.
conclusionThis bibliometric mapping provides a comprehensive overview of global research on anti-angiogenic therapy for GC from 2000 to 2024. These findings delineate influential contributors, evolving research priorities, and emerging therapeutic strategies, and offer valuable guidance for future basic and clinical studies in this rapidly advancing field.
Indexed as
Identifiers
41284207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.